



Your day-by-day guide to ASCO

30 May - 3 June 2008

*McCormick Place
Chicago, IL, USA*



Contents

Congress details 2

Dining 3

Safety 4

Congress site plan 6

Floor plans 8

Key 11

Saturday 31 May 12

Sunday 1 June 14

Monday 2 June 17

Tuesday 3 June 20

Hotels 22

Map 23

Congress details

Congress venue

McCormick Place
2301 South Lake Shore Drive
Chicago, IL 60616, USA
Tel: 312 791 7000; Fax: 312 791 6543

Congress registration

Location: Lakeside Center, Hall E, McCormick Place
Friday 30 May: Onsite registration opens (including self-registration)
Tuesday 3 June: Onsite registration closes

Congress dates and opening hours

| | |
|-----------------|-------------|
| Friday 30 May | 13:00-18:00 |
| Saturday 31 May | 08:00-18:00 |
| Sunday 1 June | 08:00-18:00 |
| Monday 2 June | 08:00-18:00 |
| Tuesday 3 June | 08:00-13:00 |

Dining

Recommended restaurants

Blue Water Grill (American Contemporary)
520 North Dearborn Street at Grand Avenue, Chicago, IL 60610
Tel: 312 777 1400

Capital Grille (American Steakhouse)
633 North St Clair Street, Chicago, IL 60611
Tel: 312 337 9400

Catch 35 (Seafood)
35 West Wacker Drive, Chicago, IL 60601
Tel: 312 346 3500

Coco Pazzo (Italian)
300 West Hubbard Street, Chicago, IL 60610
Tel: 312 836 0900

Everest Restaurant (American Contemporary)
440 South La Salle Street, 40th Floor, Chicago, IL 60605
Tel: 312 663 8920

McCormick & Schmick's (Seafood)
1 East Wacker Drive, Chicago, IL 60601
Tel: 312 923 7226

Morton's (Steak and Seafood)
65 East Wacker Place, Chicago, IL 60601
Tel: 312 201 0410

N9NE Steak House (American Steakhouse)
440 West Randolph Street, Chicago, IL 60606
Tel: 312 575 9900

Ruth's Chris Steak House (American Steakhouse)
431 North Dearborn Street, Chicago, IL 60610
Tel: 312 321 2725

Santorini (Greek)
800 West Adams Street, Chicago, IL 60661
Tel: 312 829 8820

Smith & Wollensky (American Steakhouse)
318 North State Street, Chicago, IL 60610
Tel: 312 670 9900

The Palm (Steak, Seafood and Italian)
323 East Wacker Drive, Chicago IL 60601
Tel: 312 616 1000

Safety

Safety tips

On leaving the congress site you are advised to remove your ASCO name badge or any Roche identity insignia

Keep jewellery or accessories to a minimum and do not display cameras or bags that can draw attention

Keep your wallet or precious belongings in your inside front pocket or wear your handbag across your shoulders

Sightsee on well-lit, well-travelled streets and passages either with a colleague or in a group

Important telephone numbers

Emergency services (Police, Ambulance, Fire): 911


Non-emergency services (Police and City Services): 311


Yellow Cab Chicago: 312 8294 222

Chicago Office of Tourism: 312 744 2400


Congress site plan

Lakeside Center
(East Building)







Floor plans




Lakeside Center



North Building



South Building



West Building

Key to symbols used throughout the planner

A Avastin

H Herceptin

M MabThera

T Tarceva

X Xeloda

GENERAL POSTER SESSION

Time: 08:00-12:00

Venue: S Hall A1

Genitourinary cancer

- A** Efficacy and safety of first-line bevacizumab (BEV) plus interferon- α 2a (IFN) in patients (pts) \geq 65 years with metastatic renal cell carcinoma (mRCC) (E Bajetta; Poster 4D, Abstract 5095)
- A** Costs of managing side effects in the treatment of first line metastatic renal cell carcinoma (mRCC) in Germany, France, and UK: Bevacizumab (BEV) + interferon alpha-2a (IFN) compared with sunitinib (G Mickisch; Poster 6H, Abstract 5110)

ORAL ABSTRACT PRESENTATION SESSION

Time: 15:00-18:00

Venue: E Hall D1

Gastrointestinal (colorectal) cancer

- A** Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer (CJ Allegra; Abstract 4006)
- A** Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) (CJ Punt; Abstract LBA4011)
- X**

Time: 15:15-15:30

Time: 16:45-17:00

ORAL ABSTRACT PRESENTATION SESSION

Time: 15:00-18:00

Venue: W375e

Genitourinary cancer (testes, kidney and bladder)



Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis (BJ Escudier; Abstract 5025)

Time: 16:15-16:30

ORAL ABSTRACT PRESENTATION SESSION

Time: 08:00-11:00

Venue: E354b

Lymphoma

- M** Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) (M Pfreundschuh; Abstract 8508)

Time: 08:45-09:00

ORAL ABSTRACT PRESENTATION SESSION

Time: 08:00-11:00

Venue: E Hall D1

Breast cancer - metastatic

- A** Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO (D Miles; Abstract LBA1011)

Time: 08:30-08:45

- H** Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study) (M Bontenbal; Abstract 1014)

Time: 09:00-09:15

- H** A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy (J O'Shaughnessy; Abstract 1015)

Time: 09:15-09:30

POSTER DISCUSSION SESSION

Time: 08:00-12:00 [discussion 11:00-12:00]

Venue: E450a [E Hall D2]

Gastrointestinal (colorectal) cancer

- A** Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT (SR Berry; Poster 12, Abstract 4025)
- A** International multi-centre randomised Phase II/III study of Capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial (T Price; Poster 16, Abstract 4029)
- X**
- A** Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604) (AC Reinacher-Schick; Poster 17, Abstract 4030)
- X** Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the German AIO CRC study group (V Heinemann; Poster 20, Abstract 4033)

GENERAL POSTER SESSION

Time: 14:00-18:00

Venue: S Hall A1

Lung cancer - metastatic

- T** MERIT: analysis of differential gene expression in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated with erlotinib (P Delmar; Poster 42A, Abstract 8046)
- A** Safety of first-line bevacizumab-based therapy with concomitant cardiovascular or anticoagulation medication in advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in MO19390 (SAiL) (F Griesinger; Poster 42D, Abstract 8049)
- A** Effects of diagnostic method and surgery on safety of first-line bevacizumab plus chemotherapy in advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL) (C-M Tsai; Poster 43E, Abstract 8058)
- T** Efficacy of erlotinib in patients (pts) with advanced non-small-cell lung cancer (NSCLC) relative to clinical characteristics: subset analyses from the TRUST study (SG Allan; Poster 46D, Abstract 8081)
- A** Safety of bevacizumab-based therapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL) (E Dansin; Poster 46H, Abstract 8085)
- T** A phase II study of first-line erlotinib in patients (pts) with stage IIIb/IV non-small-cell lung cancer (NSCLC) including dose escalation to toxicity in current and former smokers (C/FS) (B Besse; Poster 51H, Abstract 8111)

GENERAL POSTER SESSION

Time: 08:00-12:00

Venue: S Hall A1

Gastrointestinal (colorectal) cancer

- X** Capecitabine and oxaliplatin as first-line treatment in patients with metastatic colorectal cancer (MCRC): A pooled analysis of randomized phase II-III trials (R Porschen; Poster 3E, Abstract 4055)
- A** Waterfall plot analysis of XELOX or XELIRI with cetuximab or bevacizumab in patients with advanced colorectal cancer (ACRC): Combined analysis of two randomized first-line phase II trials of the AIO CRC study group (D Arnold; Poster 5E, Abstract 4067)
- X**
- A** The safety of long-term bevacizumab use: Results from the BRiTE observational cohort study (OCS) (D Purdie; Poster 14G, Abstract 4103)

POSTER DISCUSSION SESSION

Time: 08:00-12:00 [discussion 12:00-13:00]

Venue: W375e lobby [W375d]

Lung cancer - metastatic

- T** FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) (JS Lee; Poster 12, Abstract 8031)
- T** Intermittent erlotinib (ERL) schedules in combination with pemetrexed (PEM): Phase I schedules designed to achieve pharmacodynamic separation (AM Davies; Poster 13, Abstract 8032)

GENERAL POSTER SESSION

Time: 14:00-18:00

Venue: S Hall A1

Breast cancer - local-regional and adjuvant therapy

- X** First report of the European Cooperative Trial in Operable Breast Cancer II (ECTO II): Effects of primary chemo-endocrine therapy on local-regional disease in ER-positive breast cancer (M Zambetti; Poster 11G, Abstract 588)

GENERAL POSTER SESSION

Time: 14:00-18:00

Venue: S Hall A1

Breast cancer - metastatic

- X** Randomized trial of first-line docetaxel + capecitabine (XT) versus docetaxel + epirubicin (ET) for metastatic breast cancer (MBC): Efficacy results of ERASME-4/CAPEDOC-EPIDOC (T Bachelot; Poster 24G, Abstract 1049)
- H** Observational Demetra study: Survival of metastatic breast carcinoma patients after treatment with trastuzumab (S Ménard; Poster 31G, Abstract 1062)
- A** A phase II trial investigating if bevacizumab in combination with hormone therapy will reverse acquired estrogen independence in metastatic breast cancer patients (C Falkson; Poster 34B, Abstract 1074)
- X** A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: A phase II study (T Traina; Poster 40H, Abstract 1101)

ORAL ABSTRACT PRESENTATION SESSION

Time: 15:00-18:00

Venue: E Hall D2

Gastrointestinal (noncolorectal) cancer

A

A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine

T

(G) in patients (pts) with metastatic pancreatic cancer (W Vervenne; Abstract 4507)

Time: 15:45-16:00

POSTER DISCUSSION SESSION

Time: 08:00-12:00 [discussion 11:00-12:00]

Venue: E450b [E354a]

Breast cancer - metastatic

- H** Capecitabine vs capecitabine vs + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3-05) (G Von Minckwitz; Poster 6, Abstract 1025)
- X**
- H** Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy (KA Gelmon; Poster 7, Abstract 1026)
- H** A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC) (M Beeram; Poster 9, Abstract 1028)
- X** Randomized, multicenter, phase III trial of docetaxel plus epirubicin (ET) with or without capecitabine (X) as first-line therapy for stage IV breast cancer (BC) (M Mansutti; Poster 15, Abstract 1034)
- A** Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC) (BJ Klencke; Poster 17, Abstract 1036)

POSTER DISCUSSION SESSION

Time: 08:00-12:00 [discussion 11:00-12:00]

Venue: S403 [S406 Vista Room]

Gastrointestinal (noncolorectal) cancer

- H** HER2-positivity rates in advanced gastric cancer (GC): results from a large international phase III trial (Y-J Bang; Poster 14, Abstract 4526)

Hotels

Avenue Hotel Chicago

160 East Huron Street,
Chicago, IL 60611
Tel: 312 787 2900
www.avenuehotelchicago.com
Breakfast: Madison / Avenue
room, 13th floor, 06:30-10:30

Blackstone Chicago

636 South Michigan Avenue,
Chicago, IL 60605
Tel: 312 447 0955
www.marriott.com
Breakfast: Room Chicago,
06:30-09:00

Chicago City Centre Hotel

300 East Ohio Street,
Chicago, IL 60611
Tel: 312 787 6100
www.chicagocitycentrehotel.com
Breakfast: Restaurant 300 East,
06:30-10:30

Congress Plaza Hotel

520 South Michigan Avenue,
Chicago, IL 60605
Tel: 312 427 3800
www.congressplazahotel.com
Breakfast: Great Hall, 2nd floor,
06:30-10:00

Hilton Chicago

720 South Michigan Avenue,
Chicago, IL 60605
Tel: 312 922 4400
www.hilton.com
Breakfast: The Pavilion,
Mon-Fri 05:30-11:00;
Sat 05:30-12:00; Sun 05:30-14:00

Hyatt Regency McCormick Place

2233 South Martin Luther King
Drive, Chicago, IL 60616
Tel: 312 567 1234
www.mccormickplace.hyatt.com
Breakfast: Shor, Grand
Concourse, 06:30-11:00

Whitehall Hotel

105 East Delaware Place,
Chicago, IL 60611
Tel: 312 944 6300
www.thewhitehallhotel.com
Breakfast: Salon I-III, 2nd floor,
06:30-10:30

Wyndham Chicago

633 North St Clair Street,
Chicago, IL 60611
Tel: 312 573 0300
www.wyndham.com
Breakfast: Caliterra, 2nd floor,
06:30-11:00

Map





F. Hoffmann-La Roche Ltd
CH-4070 Basel
Switzerland



10%
TOTAL RECOVERED FIBER
ALL POST-CONSUMER FIBER